Skip to main content

Advertisement

SpringerLink
Log in

Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Attenuated strains of Sabin poliovirus vaccine replicate in the human gut and, in rare cases, may cause vaccine-associated paralytic poliomyelitis (VAPP). The genetic instability of Sabin strains constitutes one of the main causes of VAPP, a disease that is most frequently associated with type 3 and type 2 Sabin strains, and more rarely with type 1 Sabin strains. In the present study, the growth phenotype of eight oral poliovirus vaccine (OPV) isolates (two non-recombinants and six recombinants), as well as of Sabin vaccine strains, was evaluated using two different assays, the reproductive capacity at different temperatures (Rct) test and the one-step growth curve test in Hep-2 cells at two different temperatures (37°C and 40°C). The growth phenotype of isolates was correlated with genomic modifications in order to identify the determinants and mechanisms of reversion towards neurovirulence. All of the recombinant OPV isolates showed a thermoresistant phenotype in the Rct test. Moreover, both recombinant Sabin-3 isolates showed significantly higher viral yield than Sabin 3 vaccine strain at 37°C and 40°C in the one-step growth curve test. All of the OPV isolates displayed mutations at specific sites of the viral genome, which are associated with the attenuated and temperature-sensitive phenotype of Sabin strains. The results showed that both mutations and recombination events could affect the phenotype traits of Sabin derivatives and may lead to the reversion of vaccinal strains to neurovirulent ones. The use of phenotypic markers along with the genomic analysis may shed additional light on the molecular determinants of the reversed neurovirulent phenotype of Sabin derivatives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wimmer E, Hellen CUT, Cao X (1993) Genetics of poliovirus. Annu Rev Genet 27:353–436

    Article  CAS  PubMed  Google Scholar 

  2. Pilipenko EV, Blinov VM, Romanova LI, Sinyakov AN, Maslova SV, Agol VI (1989) Conserved structural domains in the 5′-untranslated region of picornaviral genomes: an analysis of the segment controlling translation and neurovirulence. Virology 168:201–209

    Article  CAS  PubMed  Google Scholar 

  3. Skinner MA, Racaniello VR, Dunn G, Cooper J, Minor PD, Almond JW (1989) New model for the secondary structure of the 5′ non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. J Mol Biol 207:379–392

    Article  CAS  PubMed  Google Scholar 

  4. Pelletier J, Kaplan G, Racaniello VR, Sonenberg N (1988) Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5′ noncoding region. Mol Cell Biol 8:1103–1112

    CAS  PubMed  Google Scholar 

  5. Sabin AB, Boulger LR (1973) History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1:115–118

    Article  Google Scholar 

  6. Christodoulou C, Colbere-Garapin F, Macadam A, Taffs LF, Marsden S, Minor P, Horaud F (1990) Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol 64:4922–4929

    CAS  PubMed  Google Scholar 

  7. Macadam AJ, Arnold C, Howlett J, John A, Marsden S, Taffs F, Reeve P, Hamada N, Wareham K, Almond J, Cammack N, Minor PD (1989) Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 172:408–414

    Article  CAS  PubMed  Google Scholar 

  8. Macadam AJ, Pollard SR, Ferguson G, Dunn G, Skuce R, Almond JW, Minor PD (1991) The 5′ noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181:451–458

    Article  CAS  PubMed  Google Scholar 

  9. Bouchard MJ, Lam DH, Racaniello VR (1995) Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 69:4972–4978

    CAS  PubMed  Google Scholar 

  10. Georgescu MM, Tardy-Panit M, Guillot S, Crainic R, Delpeyroux F (1995) Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus. J Virol 69:5278–5286

    CAS  PubMed  Google Scholar 

  11. Kawamura N, Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A (1989) Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 63:1302–1309

    CAS  PubMed  Google Scholar 

  12. Omata T, Kohara M, Kuge S, Komatsu T, Abe S, Semler BL, Kameda A, Itoh H, Arita M, Wimmer E, Nomoto A (1986) Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol 58:348–358

    CAS  PubMed  Google Scholar 

  13. Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F (1993) A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. J Virol 67:4630–4638

    CAS  PubMed  Google Scholar 

  14. Otelea D, Guillot S, Furione M, Combiescu AA, Balanant J, Candrea A, Crainic R (1993) Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Dev Biol Stand 78:33–38

    CAS  PubMed  Google Scholar 

  15. Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD (1991) Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 164(1):191–194

    CAS  PubMed  Google Scholar 

  16. Minor PD, Dunn G, Evans DM, Magrath DI, John A, Howlett J, Phillips A, Westrop G, Wareham K, Almond JW, Hogle JM (1989) The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J Gen Virol 70:1117–1123

    Article  CAS  PubMed  Google Scholar 

  17. Westrop GD, Wareham KA, Evans DM, Dunn G, Minor PD, Magrath DI, Taffs F, Marsden S, Skinner MA, Schild GC, Almond JW (1989) Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 63:1338–1344

    CAS  PubMed  Google Scholar 

  18. Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP (2004) Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J Virol 78:11097–11107

    Article  CAS  PubMed  Google Scholar 

  19. Gutiérrez AL, Denova-Ocampo M, Racaniello VR, del Angel RM (1997) Attenuating mutations in the poliovirus 5′ untranslated region alter its interaction with polypyrimidine tract-binding protein. J Virol 71:3826–3833

    PubMed  Google Scholar 

  20. Evans DM, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel JV Jr (1985) Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314(6011):548–550

    Article  CAS  PubMed  Google Scholar 

  21. Gnanashanmugam D, Falkovitz-Halpern MS, Dodge A, Fang M, Wong LJ, Esparza M, Hammon R, Rivas-Merelles EE, Santos JI, Maldonado Y (2007) Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay. J Clin Microbiol 45(8):2419–2425

    Article  CAS  PubMed  Google Scholar 

  22. Martinez CV, Old MO, Kwock DK, Khan SS, Garcia JJ, Chan CS, Webster R, Falkovitz-Halpern MS, Maldonado YA (2004) Shedding of sabin poliovirus Type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J Infect Dis 190(2):409–416

    Article  CAS  PubMed  Google Scholar 

  23. Centers for Disease Control and Prevention (CDC) (1997) Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 46:1–25

    Google Scholar 

  24. Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R (1993) Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196:199–208

    Article  CAS  PubMed  Google Scholar 

  25. Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, Combiescu AA, Crainic R, Delpeyroux F (1997) Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 71:7758–7768

    CAS  PubMed  Google Scholar 

  26. Cherkasova EA, Yakovenko ML, Rezapkin GV, Korotkova EA, Ivanova OE, Eremeeva TP, Krasnoproshina LI, Romanenkova NI, Rozaeva NR, Sirota L, Agol VI, Chumakov KM (2005) Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J Virol 79:1062–1070

    Article  CAS  PubMed  Google Scholar 

  27. Yakovenko ML, Korotkova EA, Ivanova OE, Eremeeva TP, Samoilovich E, Uhova I, Gavrilin GV, Agol VI (2009) Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance. J Virol 83(7):3402–3406

    Article  CAS  PubMed  Google Scholar 

  28. Georgopoulou A, Markoulatos P, Spyrou N, Vamvakopoulos NC (2000) Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications. J Clin Microbiol 38:4337–4342

    CAS  PubMed  Google Scholar 

  29. Balanant J, Guillot S, Candrea A, Delpeyroux F, Crainic R (1991) The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay. Virology 184:645–654

    Article  CAS  PubMed  Google Scholar 

  30. Mulders MN, Reimerink JH, Stenvik M, Alaeddinoglu I, van der Avoort HG, Hovi T, Koopmans MP (1999) A Sabin vaccine-derived field isolate of poliovirus type 1 displaying aberrant phenotypic and genetic features, including a deletion in antigenic site 1. J Gen Virol 80:907–916

    CAS  PubMed  Google Scholar 

  31. Dedepsidis E, Karakasiliotis I, Paximadi E, Kyriakopoulou Z, Komiotis D, Markoulatos P (2006) Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine. Virus Genes 33:183–191

    Article  CAS  PubMed  Google Scholar 

  32. Karakasiliotis I, Markoulatos P, Katsorchis T (2004) Site analysis of recombinant and mutant poliovirus isolates of Sabin origin from patients and from vaccinees. Mol Cell Probes 18:103–109

    Article  CAS  PubMed  Google Scholar 

  33. Paximadi E, Karakasiliotis I, Mamuris Z, Stathopoulos C, Krikelis V, Markoulatos P (2006) Genomic analysis of recombinant sabin clinical isolates. Virus Genes 32:203–210

    Article  CAS  PubMed  Google Scholar 

  34. Nakano JH, Hatch MH, Thieme ML, Nottay B (1978) Parameters for differentiating vaccine-derived and wild poliovirus strains. Prog Med Virol 24:178–206

    CAS  PubMed  Google Scholar 

  35. Malnou CE, Pöyry TA, Jackson RJ, Kean KM (2002) Poliovirus internal ribosome entry segment structure alterations that specifically affect function in neuronal cells: molecular genetic analysis. J Virol 76(21):10617–10626

    Article  CAS  PubMed  Google Scholar 

  36. Rezapkin GV, Chumakov KM, Lu Z, Ran Y, Dragunsky EM, Levenbook IS (1994) Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology 202:370–378

    Article  CAS  PubMed  Google Scholar 

  37. Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, Chumakov KM, Agol VI (2002) Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 76:6791–6799

    Article  CAS  PubMed  Google Scholar 

  38. Minor PD, Ferguson M, Evans DM, Almond JW, Icenogle JP (1986) Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 67:1283–1291

    Article  CAS  PubMed  Google Scholar 

  39. Harber J, Bernhardt G, Lu HH, Sgro JY, Wimmer E (1995) Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. Virology 214:559–570

    Article  CAS  PubMed  Google Scholar 

  40. He Y, Bowman VD, Mueller S, Bator CM, Bella J, Peng X, Baker TS, Wimmer E, Kuhn RJ, Rossmann MG (2000) Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci USA 97:79–84

    Article  CAS  PubMed  Google Scholar 

  41. Muzychenko AR, Lipskaya GYu, Maslova SV, Svitkin YV, Pilipenko EV, Nottay BK, Kew OM, Agol VI (1991) Coupled mutations in the 5′-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications. Virus Res 21:111–122

    Article  CAS  PubMed  Google Scholar 

  42. Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW, Minor PD (1993) Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192:18–26

    Article  CAS  PubMed  Google Scholar 

  43. Minor PD, Macadam AJ, Stone DM, Almond JW (1993) Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 21:357–363

    Article  CAS  PubMed  Google Scholar 

  44. Guillot S, Otelea D, Delpeyroux F, Crainic R (1994) Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine 12:503–507

    Article  CAS  PubMed  Google Scholar 

  45. Georgescu MM, Delpeyroux F, Tardy-Panit M, Balanant J, Combiescu M, Combiescu AA, Guillot S, Crainic R (1994) High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 68:8089–8101

    CAS  PubMed  Google Scholar 

  46. Friedrich F (1996) Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Acta Virol 40:157–170

    CAS  PubMed  Google Scholar 

  47. Equestre M, Genovese D, Cavalieri F, Fiore L, Santoro R, Perez Bercoff R (1991) Identification of a consistent pattern of mutations in neurovirulent variants derived from the sabin vaccine strain of poliovirus type 2. J Virol 65:2707–2710

    CAS  PubMed  Google Scholar 

  48. La Monica N, Almond JW, Racaniello VR (1987) A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans. J Virol 61:2917–2920

    PubMed  Google Scholar 

  49. La Monica N, Racaniello VR (1989) Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y. J Virol 63:2357–2360

    PubMed  Google Scholar 

  50. Chumakov KM, Powers LB, Noonan KE, Roninson IB, Levenbook IS (1991) Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci USA 88:199–203

    Article  CAS  PubMed  Google Scholar 

  51. Pliaka V, Dedepsidis E, Kyriakopoulou Z, Papadopoulou I, Levidiotou S, Markoulatos P (2007) Use of mutational pattern in 5′-NCR and VP1 regions of polioviruses for molecular diagnosis. Mol Cell Probes 21:267–275

    Article  CAS  PubMed  Google Scholar 

  52. Pliaka V, Dedepsidis E, Kyriakopoulou Z, Papadi G, Tsakogiannis D, Pratti A, Levidiotou-Stefanou S, Markoulatos P (2010) Growth kinetic analysis of bi-recombinant poliovirus vaccine strains. Virus Genes 40(2):200–211

    Article  CAS  PubMed  Google Scholar 

  53. Weeks-Levy C, Tatem JM, DiMichele SJ, Waterfield W, Georgiu AF, Mento SJ (1991) Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. Virology 185:934–937

    Article  CAS  PubMed  Google Scholar 

  54. Tatem JM, Weeks-Levy C, Georgiu A, DiMichele SJ, Gorgacz EJ, Racaniello VR, Cano FR, Mento SJ (1992) A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J Virol 66:3194–3197

    CAS  PubMed  Google Scholar 

  55. Mento SJ, Weeks-Levy C, Tatem JM, Gorgacz EJ, Waterfield WF (1993) Significance of a newly identified attenuating mutation in Sabin 3 oral poliovirus vaccine. Dev Biol Stand 78:93–100

    CAS  PubMed  Google Scholar 

  56. Fricks CE, Hogle JM (1990) Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol 64:1934–1945

    CAS  PubMed  Google Scholar 

  57. Martin A, Benichou D, Couderc T, Hogle JM, Wychowski C, Van der Werf S, Girard M (1991) Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model. Virology 180:648–658

    Article  CAS  PubMed  Google Scholar 

  58. McGoldrick A, Macadam AJ, Dunn G, Rowe A, Burlison J, Minor PD, Meredith J, Evans DJ, Almond JW (1995) Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 69:7601–7605

    CAS  PubMed  Google Scholar 

  59. Paul AV, Rieder E, Kim DW, van Boom JH, Wimmer E (2000) Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. J Virol 74:10359–10370

    Article  CAS  PubMed  Google Scholar 

  60. Rieder E, Paul AV, Kim DW, van Boom JH, Wimmer E (2000) Genetic and biochemical studies of poliovirus cis-acting replication element cre in relation to VPg uridylylation. J Virol 74:10371–10380

    Article  CAS  PubMed  Google Scholar 

  61. Martín J, Odoom K, Tuite G, Dunn G, Hopewell N, Cooper G, Fitzharris C, Butler K, Hall WW, Minor PD (2004) Long-term excretion of vaccine-derived poliovirus by a healthy child. J Virol 78:13839–13847

    Article  PubMed  Google Scholar 

  62. Horie H, Yoshida H, Matsuura K, Miyazawa M, Wakabayashi K, Nomoto A, Hashizume S (2002) Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J Med Virol 68:445–451

    Article  PubMed  Google Scholar 

  63. Cello J, Toyoda H, Dejesus N, Dobrikova EY, Gromeier M, Wimmer E (2008) Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. J Med Virol 80:352–359

    Article  CAS  PubMed  Google Scholar 

  64. Malnou CE, Werner A, Borman AM, Westhof E, Kean KM (2004) Effects of vaccine strain mutations in domain V of the internal ribosome entry segment compared in the wild type poliovirus type 1 context. J Biol Chem 279:10261–10269

    Article  CAS  PubMed  Google Scholar 

  65. De Jesus N, Franco D, Paul A, Wimmer E, Cello J (2005) Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence. J Virol 79:14235–14243

    Article  PubMed  Google Scholar 

  66. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR (1992) Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14:568–579

    CAS  PubMed  Google Scholar 

  67. Strebel PM, Aubert-Combiescu A, Ion-Nedelcu N, Biberi-Moroeanu S, Combiescu M, Sutter RW, Kew OM, Pallansch MA, Patriarca PA, Cochi SL (1994) Paralytic poliomyelitis in Romania, 1984–1992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. Am J Epidemiol 140:1111–1124

    CAS  PubMed  Google Scholar 

  68. Cuervo NS, Guillot S, Romanenkova N, Combiescu M, Aubert-Combiescu A, Seghier M, Caro V, Crainic R, Delpeyroux F (2001) Genomic features of intertypic recombinant sabin poliovirus strains excreted by primary vaccinees. J Virol 75:5740–5751

    Article  CAS  PubMed  Google Scholar 

  69. Driesel G, Diedrich S, Kunkel U, Schreier E (1995) Vaccine-associated cases of poliomyelitis over a 30 year period in East Germany. Eur J Epidemiol 11:647–654

    Article  CAS  PubMed  Google Scholar 

  70. Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI (2000) Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J Virol 74:7381–7390

    Article  CAS  PubMed  Google Scholar 

  71. Savolainen-Kopra C, Samoilovich E, Kahelin H, Hiekka AK, Hovi T, Roivainen M (2009) Comparison of poliovirus recombinants: accumulation of point mutations provides further advantages. J Gen Virol 90(Pt 8):1859–1868

    Article  CAS  PubMed  Google Scholar 

  72. Friedrich F, Filippis AM, Ferreira FC, Schatzmayr HG, Da-Silva EE (1995) Genomic characterization of type 2 polioviruses isolated from vaccine-associated cases in Brazil. Braz J Med Biol Res 28(7):733–742

    CAS  PubMed  Google Scholar 

  73. Blomqvist S, Bruu AL, Stenvik M, Hovi T (2003) Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1. J Gen Virol 84:573–580

    Article  CAS  PubMed  Google Scholar 

  74. Martín J, Samoilovich E, Dunn G, Lackenby A, Feldman E, Heath A, Svirchevskaya E, Cooper G, Yermalovich M, Minor PD (2002) Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J Virol 76:10921–10928

    Article  PubMed  Google Scholar 

  75. Paximadi E, Karakasiliotis I, Bolanaki E, Krikelis A, Markoulatos P (2007) Vaccine derived bi- and multi-recombinant Sabin strains. Virus Genes 35:541–548

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by research grants from the Postgraduate Program “Applications of Molecular Biology-Genetics. Diagnostic Biomarkers”, code 3817, of the University of Thessaly, School of Health Sciences, Department of Biochemistry and Biotechnology.

Author information

Authors and Affiliations

  1. Department of Biochemistry and Biotechnology, Microbiology–Virology Laboratory, University of Thessaly, School of Health Sciences, Ploutonos 26 and Aiolou Str., 41221, Larissa, Greece

    V. Pliaka, Z. Kyriakopoulou, D. Tsakogiannis, I. G. A. Ruether & P. Markoulatos

  2. Department of Microbiology, University of Ioannina, Medical School, Ioannina, Greece

    C. Gartzonika & S. Levidiotou-Stefanou

  3. LUX Innovate Ltd., Edinburgh, UK

    A. Krikelis

Authors
  1. V. Pliaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Kyriakopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Tsakogiannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. G. A. Ruether
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Gartzonika
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Levidiotou-Stefanou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Krikelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Markoulatos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Markoulatos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pliaka, V., Kyriakopoulou, Z., Tsakogiannis, D. et al. Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains. Eur J Clin Microbiol Infect Dis 29, 1513–1523 (2010). https://doi.org/10.1007/s10096-010-1033-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-010-1033-9

Keywords

Search

Navigation